In conclusion, these studies showed that the use of an agent that intensifies mitochondrial oxidative stress in combination with a specific FLT3 inhibitor may represent a useful strategy to improve elimination of AML cells to treat FLT3 mutated AMLs. Here, FLT3 is linked to acute myeloid leukemia.